Oral A. muciniphila supplementation improved clinical responses to immune checkpoint inhibitors targeting the PD-1/PD-L1 (programmed death-1/programmed death ligand-1) axis in animal studies (35), and A. muciniphila reduced biomarkers of liver dysfunction and inflammation among persons who were overweight or obese (36); however, no studies have investigated its effect on child growth or diarrhea. The gene discussed is CD274; the disease is Decreased liver function.